Sanofi and Translate Bio to Advance MRT5500 into Clinical Study Against COVID-19

 Sanofi and Translate Bio to Advance MRT5500 into Clinical Study Against COVID-19

Sanofi and Translate Bio to Advance MRT5500 into Clinical Study Against COVID-19

Shots:

  • The companies reported the preclinical results of MRT5500 demonstrating the potential of the vaccine in neutralizing the Abs against SARS-CoV-2. The two doses of MRT5500 induced neutralizing antibody levels significantly higher than those observed in COVID-19 patients
  • The preclinical data support the advancement of MRT5500 for clinical development. The companies anticipate the initiation of P-I/II study in Q4’20
  • MRT5500 is being developed under the collaboration between Sanofi Pasteur and Translate Bio and has demonstrated its ability to elicit an immune response in both mice and non-human primates in a preclinical study

Click here ­to­ read full press release/ article | Ref: Sanofi | Image: Business Line


Post Views:
11